SALVATORE, Giuliana
 Distribuzione geografica
Continente #
NA - Nord America 7.602
EU - Europa 4.115
AS - Asia 2.017
SA - Sud America 351
AF - Africa 44
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 4
Totale 14.154
Nazione #
US - Stati Uniti d'America 7.549
RU - Federazione Russa 1.555
UA - Ucraina 676
SG - Singapore 607
VN - Vietnam 592
CN - Cina 572
IT - Italia 422
SE - Svezia 345
GB - Regno Unito 312
DE - Germania 304
BR - Brasile 259
FR - Francia 175
FI - Finlandia 101
NL - Olanda 83
HK - Hong Kong 44
IN - India 33
PL - Polonia 30
AR - Argentina 29
CA - Canada 23
BD - Bangladesh 22
AT - Austria 20
PK - Pakistan 20
TR - Turchia 20
EU - Europa 19
ZA - Sudafrica 19
CO - Colombia 18
BE - Belgio 15
EC - Ecuador 15
IQ - Iraq 15
MX - Messico 15
IE - Irlanda 14
CZ - Repubblica Ceca 13
JP - Giappone 13
MY - Malesia 11
LV - Lettonia 9
PH - Filippine 9
VE - Venezuela 9
PY - Paraguay 8
MA - Marocco 7
PE - Perù 7
SA - Arabia Saudita 7
UZ - Uzbekistan 7
AZ - Azerbaigian 6
IL - Israele 6
KR - Corea 5
PT - Portogallo 5
BG - Bulgaria 4
ES - Italia 4
RO - Romania 4
TN - Tunisia 4
AE - Emirati Arabi Uniti 3
BY - Bielorussia 3
DZ - Algeria 3
EG - Egitto 3
ID - Indonesia 3
KG - Kirghizistan 3
KZ - Kazakistan 3
MK - Macedonia 3
SN - Senegal 3
TT - Trinidad e Tobago 3
UY - Uruguay 3
AL - Albania 2
AM - Armenia 2
AU - Australia 2
BZ - Belize 2
CH - Svizzera 2
CL - Cile 2
DK - Danimarca 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
IR - Iran 2
JO - Giordania 2
LK - Sri Lanka 2
NG - Nigeria 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
RS - Serbia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AO - Angola 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BT - Bhutan 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
HR - Croazia 1
JM - Giamaica 1
KE - Kenya 1
KN - Saint Kitts e Nevis 1
LT - Lituania 1
MC - Monaco 1
MM - Myanmar 1
NO - Norvegia 1
NP - Nepal 1
PA - Panama 1
PR - Porto Rico 1
PS - Palestinian Territory 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 14.151
Città #
Fairfield 965
Woodbridge 707
Houston 587
Ashburn 518
Chandler 454
Ann Arbor 444
Seattle 395
San Jose 392
Dong Ket 377
Wilmington 377
Cambridge 327
Dallas 295
Singapore 279
Moscow 272
The Dalles 257
Nyköping 220
Dearborn 207
Jacksonville 177
Boardman 157
Southend 146
Naples 121
Beijing 112
Ho Chi Minh City 93
Napoli 76
Princeton 70
Lawrence 64
Groningen 63
Grafing 59
Yubileyny 58
New York 57
Ogden 52
Hanoi 44
Munich 43
Helsinki 42
Shanghai 42
Hong Kong 36
San Diego 36
Los Angeles 35
Des Moines 27
Düsseldorf 26
Milan 24
Formia 23
São Paulo 23
Frankfurt am Main 20
London 20
Jinan 18
Norwalk 17
Santa Clara 17
Chicago 16
Lauterbourg 15
Warsaw 15
Brussels 14
Hefei 14
Rome 14
Kunming 13
Orem 13
Tokyo 13
Boydton 12
Da Nang 12
Vienna 12
Auburn Hills 11
Council Bluffs 11
Dublin 11
Kraków 11
Amsterdam 10
Atlanta 10
Boston 10
Nanjing 10
Medellín 9
Redmond 9
Riga 9
Afragola 8
Bremen 8
Buenos Aires 8
Edinburgh 8
Haiphong 8
Lahore 8
Nocera Inferiore 8
Redwood City 8
Brno 7
Guayaquil 7
Tashkent 7
Chennai 6
Nanchang 6
Nuremberg 6
Rio de Janeiro 6
Shenyang 6
Stockholm 6
Tampa 6
Turku 6
Baku 5
Brooklyn 5
Casoria 5
Curitiba 5
Guangzhou 5
Johannesburg 5
Kilburn 5
Montreal 5
Nocera Superiore 5
Porto Alegre 5
Totale 9.328
Nome #
Extracellular superoxide dismutase is a thyroid differentiation marker down-regulated in cancer 349
TWIST1/miR-584/TUSC2 pathway induces resistance to apoptosis in thyroid cancer cells 304
Unveiling the miRNAs responsive to physical activity/exercise training in cancer: A systematic review 292
A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma 281
Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer 277
Junctional adhesion molecule-A is down-regulated in anaplastic thyroid carcinomas and reduces cancer cell aggressiveness by modulating p53 and GSK3 α/β pathways 276
Long-term recreational football training and health in aging 268
Anterior gradient protein 2 promotes survival, migration and invasion of papillary thyroid carcinoma cells 257
Anaplastic Thyroid Carcinoma: Molecular Tools for Diagnosis and Therapy 251
Cytostatic Activity of Adenosine Triphosphate-Competitive Kinase Inhibitors in BRAF Mutant Thyroid Carcinoma Cells 243
RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma 241
BAY 43-9006 inhibition of oncogenic RET mutants. 241
Identification of polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma 239
Imaging of thyroid tumor angiogenesis with microbubbles targeted to vascular endothelial growth factor receptor type 2 in mice. 238
miR-650 promotes motility of anaplastic thyroid cancer cells by targeting PPP2CA 236
A set of miRNAs participates in the cellular senescence program in human diploid fibroblasts. 231
YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes 227
Multimodal imaging for a theranostic approach in a murine model of B-cell lymphoma with engineered nanoparticles 227
Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma 222
Preclinical Imaging for the Study of Mouse Models of Thyroid Cancer 221
The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumor foci in multifocal papillary thyroid carcinoma 220
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma 219
Identification of targets of twist1 transcription factor in thyroid cancer cells. 218
Glial cell line-derived neurotrophic factor induces proliferative inhibition of NT2/D1 cells through RET-mediated up-regulation of the cyclin-dependent kinase inhibitor p27(kip1) 218
Different mutations of the RET gene cause different human tumoral diseases 216
BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas 211
Receptor tyrosine kinase inhibitors in thyroid cancer 209
BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas 209
Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins 207
High-Frequency Ultrasound-Guided Injection for the Generation of a Novel Orthotopic Mouse Model of Human Thyroid Carcinoma 205
Dissecting the molecular pathways involved in the effects of physical activity on breast cancers cells: A narrative review 203
DNA immunization followed by a single boost with cells: a protein-free immunization protocol for production of monoclonal antibodies against the native form of membrane proteins 201
Generation and characterization of novel monoclonal antibodies to the Ret receptor tyrosine kinase 201
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells 201
Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma 197
Only the substitution of methionine 918 with a threonine and not with other residues activates RET transforming potential 194
FOXM1 is a molecular determinant of the mitogenic and invasive phenotype of anaplastic thyroid carcinoma. 194
Glial cell line-derived neutrotrophic factor and neurturin can act as paracrine growth factors stimulating DNA synthesis of Ret-expressing spermatogonia 191
Osteopontin is overexpressed in human papillary thyroid carcinomas and enhances thyroid carcinoma cell invasiveness 190
Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins 182
Morphological ultrasound microimaging of thyroid in living mice 180
Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease 178
PATE, a gene expressed in prostate cancer, normal prostate, and testis, identified by a functional genomic approach 178
Identification of a novel subtype of H4-RET rearrangement in a thyroid papillary carcinoma and lymph node metastasis 178
Novel candidate genes of thyroid tumourigenesis identified in Trk-T1 transgenic mice. 176
Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas 175
High Frequency Ultrasound for the development of an Orthotopic mouse model of Human Follicular Thyroid Carcinoma 175
MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer 174
Presence of BRAF V600E in Very Early Stages of Papillary Thyroid Carcinoma 169
Heterogeneity in the distribution of RET/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas 168
TWIST1 plays a pleiotropic role in determining the anaplastic thyroid cancer phenotype 165
Pros and cons of cellular studies in developing new drugs for thyroid cancers 164
Monitoring training in non-professional soccer players by coupling SSGs and GPS technology: effects of pitch size and players role 161
Molecular biology of the MEN2 gene 159
Molecular profile of hyalinizing trabecular tumors of the thyroid: high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations 159
miR-622 Is a Novel Potential Biomarker of Breast Carcinoma and Impairs Motility of Breast Cancer Cells Through Targeting NUAK1 Kinase 158
Mitogenic effects of the up-regulation of MiniChromosome Maintenance proteins (MCM) in anaplastic thyroid carcinoma 157
Regular football training down-regulates miR-1303 muscle expression in veterans 155
Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display 153
Adiponectin and leptin exert antagonizing effects on proliferation and motility of papillary thyroid cancer cell lines 151
Frequent mutation of PIK3CA in Anaplastic Thyroid Cancer 149
The different RET-activating capability of mutations of cysteine 620 or cysteine 634 correlates with the multiple endocrine neoplasia type 2 disease phenotype 145
RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes 140
Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma 137
Effects of Annurca Flesh Apple Polyphenols in Human Thyroid Cancer Cell Lines 134
High prevalence of RET/PTC rearrangements in Ukrainian and Belarussia post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant 131
The TUSC2 Tumour Suppressor Inhibits the Malignant Phenotype of Human Thyroid Cancer Cells via SMAC/DIABLO Protein 128
miR-331-5p Affects Motility of Thyroid Cancer Cell Lines and Regulates BID Expression 124
Preclinical Imaging Evaluation of miRNAs' Delivery and Effects in Breast Cancer Mouse Models: A Systematic Review 109
The lncRNA TEX41 is upregulated in pediatric B-Cells Acute Lymphoblastic Leukemia and it is necessary for leukemic cell growth 91
Insight into the Role of the miR-584 Family in Human Cancers 89
Development of Cyclic Peptides Targeting the Epidermal Growth Factor Receptor in Mesenchymal Triple-Negative Breast Cancer Subtype 86
Exercise’s impact on lung cancer molecular mechanisms: a current overview 84
Association of radiomic features with genomic signatures in thyroid cancer: a systematic review. 76
Novel Biological Strategies for Melanoma Therapy: A Focus on lncRNAs and Their Targeting 74
Aberrant Expression of Non-Coding RNAs in Pediatric T Acute Lymphoblastic Leukemia and Their Potential Application as Biomarkers 68
Nanogel-Mediated Delivery of Doxorubicin and Curcumin in Thyroid Cancer Cells 66
Lipid-Polymer Nanoparticles (LiPoNs) Mediated Codelivery of AntimiR-21 and Gadolinium Chelate in Triple Negative Breast Cancer Theranostics 14
Totale 14.385
Categoria #
all - tutte 56.318
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 56.318


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021541 0 0 0 0 0 0 0 0 0 0 50 491
2021/2022783 53 140 26 199 16 24 108 53 71 41 47 5
2022/20231.485 144 91 140 172 229 216 56 161 159 44 55 18
2023/2024390 29 29 34 23 11 48 19 14 79 23 26 55
2024/20252.981 60 230 36 60 34 293 624 987 148 114 306 89
2025/20262.403 166 294 212 137 162 63 427 316 321 233 72 0
Totale 14.385